William Blair & Company
VIGL

William Blair & Company’s Vigil Neuroscience VIGL Stock Holding History

William Blair & Company’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,033,577
Closed -$1.84M – 1903
2025
Q1 		$1.84M Buy
1,033,577
+709,677
+219% +$1.59M 0.01% 732
2024
Q4 		$551K Buy
+323,900
New +$956K ﹤0.01% 1070

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

William Blair & Company's VIGL Position: Q2 2025 in Review

William Blair & Company sold out of Vigil Neuroscience (VIGL) in Q2 2025, closing a stake of 1,033,577 shares — an estimated $1.84M sold.

William Blair & Company first reported a position in VIGL in Q4 2024 and held it in 2 quarters. The position peaked at $1.84M in Q1 2025. 78 funds tracked by Wall St. Rank hold VIGL as of Q2 2025.

  • William Blair & Company reported no remaining Vigil Neuroscience position as of Q2 2025 after selling out during the quarter.
  • William Blair & Company sold 1,033,577 Vigil Neuroscience shares in Q2 2025, an estimated $1.84M.
  • William Blair & Company first reported a position in Vigil Neuroscience in Q4 2024 and held it in 2 quarters.
  • William Blair & Company's Vigil Neuroscience position peaked at $1.84M in Q1 2025.
  • 78 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2025.

Based on William Blair & Company's 13F filing for Q2 2025, filed 24 Jul 2025.